INSMED Inc
INSMNasdaq
$108.32
↑ +0.8%Jul 17 close · end-of-day
Price
1Y↑ +3.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$23.3B
Enterprise Value
$22.7B
P/E
—
P/S
28.5
P/B
33.1
EV/EBITDA
—
PEG
—
FCF Yield
-4.0%
Dividend Yield
—
Revenue (TTM)
$819.6M
Net Income (TTM)
-$1.2B
Free Cash Flow (TTM)
-$921.6M
Gross Margin
—
Operating Margin
-140.6%
Net Margin
-144.4%
ROE
-167.9%
ROIC
-3863.8%
Debt / Equity
0.8
Net Cash
$681.3M
Return 1Y
+4.0%
Company profile
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1.
- CEO
- William H. Lewis
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 740
- Headquarters
- New Jersey
- Website
- insmed.com
Management & directors
- Lewis WilliamChair and CEO
- Flammer Martina M.D.Chief Medical Officer
- Butera SamueleSVP, GM, Global Respiratory
- Smith Michael AlexanderChief Legal Officer
- Adsett RogerChief Operating Officer
- Bonstein SaraChief Financial Officer
- Schaeffer Orlov S NicoleChief People Strategy Officer
Roles derived from SEC Form 4 filings.
Earnings
INSM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$306.0M↑ +229.6%
Diluted EPS-$0.76↓ -46.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $164.4M | $188.5M | $245.4M | $305.2M | $363.7M | $606.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$265.2M | -$375.1M | -$457.3M | -$709.6M | -$878.3M | -$1.2B |
| Net income | -$294.1M | -$434.7M | -$481.5M | -$749.6M | -$913.8M | -$1.3B |
| Diluted EPS | -$3.01 | -$3.88 | -$3.91 | -$5.34 | -$5.57 | -$6.42 |
| Operating cash flow | -$219.3M | -$363.3M | -$400.4M | -$536.2M | -$683.9M | -$935.0M |
| Free cash flow | -$225.6M | -$370.6M | -$410.3M | -$549.5M | -$705.8M | -$967.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -161.3% | -199.0% | -186.4% | -232.5% | -241.5% | -205.6% |
| Net margin | -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $90.3M | $93.4M | $104.4M | $92.8M | $107.4M | $142.3M | $263.8M | $306.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$288.9M | -$213.4M | -$230.4M | -$248.1M | -$312.9M | -$366.0M | -$319.7M | -$153.3M |
| Net income | -$300.6M | -$220.5M | -$235.5M | -$256.6M | -$321.7M | -$370.0M | -$328.5M | -$163.6M |
| Diluted EPS | -$1.94 | -$1.27 | -$1.30 | -$1.42 | -$1.70 | -$1.75 | -$1.55 | -$0.76 |
| Operating cash flow | -$123.0M | -$180.9M | -$196.0M | -$262.1M | -$205.6M | -$219.8M | -$247.6M | -$222.7M |
| Free cash flow | -$129.7M | -$184.6M | -$202.8M | -$272.2M | -$209.1M | -$222.2M | -$264.2M | -$226.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -319.8% | -228.4% | -220.6% | -267.3% | -291.3% | -257.1% | -121.2% | -50.1% |
| Net margin | -332.8% | -236.0% | -225.5% | -276.4% | -299.5% | -260.0% | -124.5% | -53.5% |
Company news
Jul 20, 2026
Jul 17, 2026
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Lewis William· Chair and CEO | Sale | 5,005 | $116.55 | $583,332.75 | filing |
| 2026-07-09 | Lewis William· Chair and CEO | Sale | 3,359 | $118.52 | $398,108.68 | filing |
| 2026-07-09 | Lewis William· Chair and CEO | Sale | 2,335 | $117.62 | $274,642.70 | filing |
| 2026-07-09 | Lewis William· Chair and CEO | Option exercise | 6,259 | $30.46 | $190,649.14 | filing |
| 2026-07-09 | Lewis William· Chair and CEO | Option exercise | 4,440 | $17.16 | $76,190.40 | filing |
| 2026-07-06 | Flammer Martina M.D.· Chief Medical Officer | Sale | 7,448 | $110.60 | $823,748.80 | filing |
| 2026-07-06 | Flammer Martina M.D.· Chief Medical Officer | Sale | 4,854 | $109.02 | $529,183.08 | filing |
| 2026-07-06 | Flammer Martina M.D.· Chief Medical Officer | Option exercise | 7,945 | $29.13 | $231,437.85 | filing |
| 2026-07-06 | Flammer Martina M.D.· Chief Medical Officer | Option exercise | 4,357 | $19.74 | $86,007.18 | filing |
| 2026-06-25 | Lewis William· Chair and CEO | Sale | 12,091 | $102.34 | $1.2M | filing |
| 2026-06-25 | Lewis William· Chair and CEO | Sale | 3,723 | $104.28 | $388,234.44 | filing |
| 2026-06-25 | Lewis William· Chair and CEO | Option exercise | 12,518 | $30.46 | $381,298.28 | filing |
| 2026-06-25 | Lewis William· Chair and CEO | Sale | 2,456 | $105.27 | $258,543.12 | filing |
| 2026-06-25 | Lewis William· Chair and CEO | Sale | 1,836 | $103.10 | $189,291.60 | filing |
| 2026-06-25 | Lewis William· Chair and CEO | Option exercise | 8,880 | $17.16 | $152,380.80 | filing |
| 2026-06-25 | Lewis William· Chair and CEO | Sale | 1,292 | $106.27 | $137,300.84 | filing |
| 2026-06-23 | Butera Samuele· SVP, GM, Global Respiratory | Award | 7,342 | — | — | filing |
| 2026-06-22 | Smith Michael Alexander· Chief Legal Officer | Sale | 1,806 | $95.82 | $173,050.92 | filing |
| 2026-06-08 | Lewis William· Chair and CEO | Sale | 6,515 | $94.03 | $612,605.45 | filing |
| 2026-06-05 | Flammer Martina M.D.· Chief Medical Officer | Sale | 1,858 | $103.78 | $192,823.24 | filing |
| 2026-06-03 | Lewis William· Chair and CEO | Sale | 7,605 | $102.27 | $777,763.35 | filing |
| 2026-06-03 | Flammer Martina M.D.· Chief Medical Officer | Sale | 2,566 | $102.27 | $262,424.82 | filing |
| 2026-06-03 | Bonstein Sara· Chief Financial Officer | Sale | 2,404 | $102.27 | $245,857.08 | filing |
| 2026-06-03 | Adsett Roger· Chief Operating Officer | Sale | 2,370 | $102.27 | $242,379.90 | filing |
| 2026-06-03 | Smith Michael Alexander· Chief Legal Officer | Sale | 2,159 | $102.27 | $220,800.93 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.